Amicus Therapeutics
Cranbury
About Amicus Therapeutics
Amicus Therapeutics is a biotechnology company that focuses on discovering, developing, and commercializing medicines for rare and genetic diseases. It develops and delivers treatment programs, including oral therapies and combination regimens for specific metabolic conditions such as Fabry and Pompe diseases, and it manages research and licensing activities for additional potential therapies like treatments for focal segmental glomerulosclerosis. The company maintains initiatives that support patient communities affected by rare disorders and collaborates with healthcare and nonprofit organizations to enhance access and advocacy for these disease groups. Amicus also engages in corporate giving programs that support educational, advocacy, and access efforts related to its therapeutic focus areas.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $500K – $1M
- Total funding: $2.4B
- Funding stage: M&A
- Last round: Post-IPO Equity (Oct 2023)
- Ticker: nasdaq:FOLD
- Website: amicusrx.com
- Phone: (609)662-200
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/amicus-therapeutics-93723 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.